ABACUS trial: preoperative atezolizumab in urothelial carcinoma
The ABACUS trial (NCT02662309), an investigator-initiated Phase II study investigating the safety and efficacy of two cycles of neoadjuvant atezolizumab in T2-T4a transitional cell carcinoma of the bl... Author: VJOncology Added: 08/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel Agent Enfortumab, a Nectin-4 Inhibitor, for Transitional Cell Carcinoma of the Bladder: Highlights from ASCO 2018 (BMIC-049)
Dr. Daniel Goldstein reviews provocative and highly promising results with enfortumab, an inhibitor of nectin-4, as a treatment for advanced transitional cell carcinoma of the bladder. Author: BeaconMedIC Added: 08/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2018 Category: Cancer & Oncology Source Type: podcasts

Does Nab-Paclitaxel Improve Outcomes Compared to Paclitaxel in Second Line Treatment of Transitional Cell Carcinoma of the Bladder (or other cancers)? Highlights from ASCO 2018 (BMIC-048)
Dr. Daniel Goldstein reviews trial results comparing nab-paclitaxel to standard paclitaxel in second line treatment of bladder cancer, comparing these results to those in breast cancer and raising que... Author: BeaconMedIC Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts

Could Immunotherapy Replace Neoadjuvant Chemo for Muscle-Invasive Transitional Cell Carcinoma? Highlights from ASCO 2018 (BMIC-047)
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including important studies evaluating the efficacy of neoadjuvant immunotherapy instead of chemotherapy for muscle-invasive t... Author: BeaconMedIC Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 28, 2018 Category: Cancer & Oncology Source Type: podcasts